Prelude Therapeutics (PRLD) Cash from Operations (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Cash from Operations data on file, last reported at 21685000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 36.65% year-over-year to 21685000.0; the trailing twelve-month figure through Mar 2026 stood at 43756000.0 (up 58.46% YoY), and the FY2025 full-year result was 56302000.0, up 45.28% from the prior year.
• Cash from Operations eased to 21685000.0 in Q1 2026, from 23119000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 23119000.0 in Q4 2025 to a low of 34231000.0 in Q1 2025.
• A 5-year average of 21862764.71 and a median of 23057000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations tumbled 49.82% in 2023 and surged 211.45% in 2025, its largest moves.
• Tracing PRLD's Cash from Operations over 5 years: stood at 22927000.0 in 2022, then slipped by 2.84% to 23578000.0 in 2023, then increased by 12.02% to 20744000.0 in 2024, then surged by 211.45% to 23119000.0 in 2025, then slumped by 193.8% to 21685000.0 in 2026.
• Business Quant data shows PRLD's Cash from Operations at 21685000.0 in Q1 2026, 23119000.0 in Q4 2025, and 19115000.0 in Q3 2025.